Fimasartan potassium trihydrate/Rosuvastatin calcium

瑞舒伐他汀钙/非马沙坦钾三水合物

Report date: 2022/01/14 13:23:58

Base Information

Drug NameFimasartan potassium trihydrate/Rosuvastatin calcium
Drug Alias NameRosuvastatin calcium+Fimasartan potassium trihydrate非马沙坦钾三水合物+瑞舒伐他汀钙Rosuvastatin calcium/Fimasartan potassium trihydrate非马沙坦钾三水合物/瑞舒伐他汀钙Fimasartan potassium trihydrate+Rosuvastatin calcium +[8] 
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsHMG-CoA reductase inhibitors
TargetsAngiotensin II Receptor Type 1HMG-CoA reductase
Therapy Area/IndicationsDyslipidemiasHypertension
Global Approved IndicationsDyslipidemiasHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2016/08/01
Country/TerritorySouth Korea
CombinationsYes Fimasartan Potassium TrihydrateRosuvastatin Calcium
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBoryung Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBoryung Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDyslipidemiasHypertension
Inactive IndicationsN/A

Other Information

ATC CodeC09D
Related LinksN/A